Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective study evaluating the activity and the safety of toremifene in patients
with primary or recurrent sporadic DTs.
Patients will be enrolled after the histological confirmation of DTs on biopsy Patients will
start at 60 mg daily and dose-escalate to 180 mg upon progression. Disease assessment will be
performed by contrast-enhanced MRI or CT scan, pain evaluation by a visual analog scale (VAS)
every 3 months for the first and second year, twice yearly thereafter. Response will be
evaluated either by RECIST and/or symptomatic relief.
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano